日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.

系统性免疫分析揭示了肝细胞癌联合免疫疗法反应的不同机制和预测性生物标志物。

Nishio Akira, Kodama Takahiro, Daiku Kazuma, Maesaka Kazuki, Tanaka Satoshi, Nozaki Yasutoshi, Kurahashi Tomohide, Matsumoto Kengo, Nawa Takatoshi, Tawara Seiichi, Tokuda Yuki, Nakabori Tasuku, Sakamori Ryotaro, Ohkawa Kazuyoshi, Miyazaki Masanori, Yamamoto Shuhei, Shigeno Satoshi, Myojin Yuta, Tahata Yuki, Hikita Hayato, Takehara Tetsuo

Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage

金诺芬(Auranofin)是通过FDA批准的药物库筛选发现的,它通过溶酶体损伤抑制HBs抗原的分泌。

Shimoda, Akiyoshi; Murai, Kazuhiro; Hikita, Hayato; Minami, Satoshi; Miyake, Takayuki; Kuriki, Shinji; Sometani, Emi; Sung, Jihyun; Shigeno, Satoshi; Higuchi, Yuichiro; Maesaka, Kazuki; Shirai, Kumiko; Tahata, Yuki; Saito, Yoshinobu; Kodama, Takahiro; Takahashi, Takeshi; Suemizu, Hiroshi; Takehara, Tetsuo

First-in-Human Study of [(211)At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)

首次人体研究:[(211)At]NaAt 作为靶向 α 疗法治疗放射性碘难治性甲状腺癌患者(Alpha-T1 试验)

Watabe, Tadashi; Mukai, Kosuke; Naka, Sadahiro; Sasaki, Hidetaka; Kamiya, Takashi; Hayakawa, Tomoaki; Fukuhara, Atsunori; Takano, Toru; Shirakami, Yoshifumi; Ooe, Kazuhiro; Shigeno, Satoshi; Okamura, Satomi; Masumura, Kazuho; Hida, Eisuke; Haba, Hiromitsu; Toyoshima, Atsushi; Isohashi, Kayako; Shimomura, Iichiro; Tomiyama, Noriyuki